<DOC>
	<DOC>NCT01469039</DOC>
	<brief_summary>The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.</brief_summary>
	<brief_title>A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Aripiprazole lauroxil</mesh_term>
	<criteria>Diagnosis of schizophrenia according to DSMIVTR criteria Has been able to achieve outpatient status for more than 3 months in the past year Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive) Resides in a stable living situation Willing and able to be confined to an inpatient study unit for 2 weeks or longer History of poor or inadequate clinical response to treatment with aripiprazole History of treatment resistance Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol) Diagnosis of current substance dependence (including alcohol) Pregnant, lactating, or breastfeeding Receipt of any antipsychotic medication by IM injection within 60 days before Screening Current involuntary hospitalization or incarceration Hospitalized for more than 30 days during the 90 days before Screening Additional inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Alkermes</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>ALKS 9072</keyword>
	<keyword>ALKS 9070</keyword>
	<keyword>aripiprazole lauroxil</keyword>
</DOC>